1
|
Doll SR: The lessons of life: Keynote
address to the nutrition and cancer conference. J Cancer Res. 52
(Suppl 7):S2024–S2029. 1992.
|
2
|
Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH
and Lee JS: Cancer statistics in korea: Incidence, mortality,
survival, and prevalence in 2011. J Cancer Res. 46:109–123.
2014.
|
3
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
4
|
Megahed M, Schön M, Selimovic D and Schön
MP: Reliability of diagnosis of melanoma in situ. Lancet.
359:1921–1922. 2002. View Article : Google Scholar : PubMed/NCBI
|
5
|
Chen J, He X, Peng H and Yang XO: Research
on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells.
Melanoma Res. 18:322–329. 2008. View Article : Google Scholar : PubMed/NCBI
|
6
|
Meier F, Satyamoorthy K, Nesbit M, Hsu MY,
Schittek B, Garbe C and Herlyn M: Molecular events in melanoma
development and progression. Front Bio Sci. 3:D1005–D1010. 1998.
View Article : Google Scholar
|
7
|
Changmin K and Bonglee K: Anti-cancer
natural products and their bioactive compounds inducing ER
stress-mediated apoptosis: A review. Nutrients. 10:10212018.
View Article : Google Scholar
|
8
|
Simone F: Modulation of apoptosis by
natural products for cancer therapy. Planta Med. 76:1075–1079.
2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Aung TN, Qu Z, Kortschak RD and Adelson
DL: Understanding the effectiveness of natural compound mixtures in
cancer through their molecular mode of action. Int J Mol Sci.
18:6562017. View Article : Google Scholar
|
10
|
Lin YJ, Liang WM, Chen CJ, Tsang H, Chiou
JS, Liu X, Cheng CF, Lin TH, Liao CC, Huang SM, et al: Network
analysis and mechanisms of action of Chinese herb-related natural
compounds in lung cancer cells. Phytomedicine. 58:1528932019.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Anna L and Krzysztof G: Anticancer
activity of natural compounds from plant and marine environment.
Int J Mol Sci. 19:35332018. View Article : Google Scholar
|
12
|
Perez-Vizcaino F and Fraga CG: Research
trends in flavonoids and health. Arch Biochem Biophys. 646:107–112.
2018. View Article : Google Scholar : PubMed/NCBI
|
13
|
Fraga CG, Croft KD, Kennedy DO and
Tomás-Barberán FA: The effects of polyphenols and other bioactives
on human health. Food Funct. 10:514–528. 2019. View Article : Google Scholar : PubMed/NCBI
|
14
|
Wang M, Firrman J, Liu L and Yam K: A
review on flavonoid apigenin: Dietary intake, ADME, antimicrobial
effects, and interactions with human gut microbiota. Biomed Res
Int. 2019:70104672019.PubMed/NCBI
|
15
|
Dixon RA and Steele CL: Flavonoids and
isoflavonoids-a gold mine for metabolic engineering. Trends Plant
Sci. 4:394–400. 1999. View Article : Google Scholar : PubMed/NCBI
|
16
|
Yin Y, Gong FY, Wu XX, Sun Y, Li YH, Chen
T and Xu Q: Antiinflammatory and immunosuppressive effect of
flavones isolated from artemisia vestita. J Ethnopharmacol.
120:1–6. 2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Chuang CM, Monie A, Wu A and Hung CF:
Combination of apigenin treatment with therapeutic HPV DNA
vaccination generates enhanced therapeutic antitumor effects. J
Biomed Sci. 16:492009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Patel D, Shukla S and Gupta S: Apigenin
and cancer chemoprevention: Progress, potential and promise. Int J
Oncol. 30:233–245. 2007.PubMed/NCBI
|
19
|
Romanová D, Vachálková A, Cipák L, Ovesná
Z and Rauko P: Study of antioxidant effect of apigenin, luteolin
and quercetin by DNA protective method. Neoplasma. 48:104–107.
2001.PubMed/NCBI
|
20
|
Fuchs J and Milbradt R: Skin
anti-inflammatory activity of apigenin-7-glucoside in rats.
Arzneimittelforschung. 43:370–372. 1993.PubMed/NCBI
|
21
|
Zhang W, Qiao H, Lv Y, Wang J, Chen X, Hou
Y, Tan R and Li E: Apigenin inhibits enterovirus-71 infection by
disrupting viral RNA association with trans-acting factors. PLoS
One. 9:e1104292014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Moon TS, Cui LG and Yang H: Involvement of
early growth response gene 1 (EGR-1) in growth suppression of the
human colonic tumor cells by apigenin and its derivative
isovitexin. J Life Sci. 17:100–115. 2007. View Article : Google Scholar
|
23
|
Tseng YH, Chien MH, Lin WL, Wen YC, Chow
JM, Chen CK, Kuo TC and Lee WJ: Inhibition of MDA-MB-231 breast
cancer cell proliferation and tumor growth by apigenin through
induction of G2/M arrest and histone H3 acetylation-mediated
p21WAF1/CIP1 expression. Environ Toxicol. 32:434–444.
2017. View Article : Google Scholar : PubMed/NCBI
|
24
|
Kaur P, Shukla S and Gupta S: Plant
flavonoid apigenin inactivates Akt to trigger apoptosis in human
prostate cancer: An in vitro and in vivo study. Carcinogenesis.
29:2210–2217. 2008. View Article : Google Scholar : PubMed/NCBI
|
25
|
Ghițu A, Schwiebs A, Radeke HH, Avram S,
Zupko I, Bor A, Pavel IZ, Dehelean CA, Oprean C, Bojin F, et al: A
comprehensive assessment of apigenin as an antiproliferative,
proapoptotic, antiangiogenic and immunomodulatory phytocompound.
Nutrients. 11:8582019. View Article : Google Scholar
|
26
|
Caltagirone S, Rossi C, Poggi A,
Ranelletti FO, Natali PG, Brunetti M, Aiello FB and Piantelli M:
Flavonoids apigenin and quercetin inhibit melanoma growth and
metastatic potential. Int J Cancer. 87:595–600. 2000. View Article : Google Scholar : PubMed/NCBI
|
27
|
Piantelli M, Rossi C, Iezzi M, La Sorda R,
Iacobelli S, Alberti S and Natali PG: Flavonoids inhibit melanoma
lung metastasis by impairing tumor cells endothelium interactions.
J Cell Physiol. 207:23–29. 2006. View Article : Google Scholar : PubMed/NCBI
|
28
|
Han SI, Kim YS and Kim TH: Role of
apoptotic and necrotic cell death under physiologic conditions. BMB
Rep. 41:1–10. 2008. View Article : Google Scholar : PubMed/NCBI
|
29
|
Evans VG: Multiple pathways to apoptosis.
Cell Biol Int Rep. 17:461–476. 1993. View Article : Google Scholar
|
30
|
Adams JM and Cory S: The Bcl-2 protein
family: Arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Danial NN and Korsmeyer SJ: Cell death:
Critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
32
|
Song Q, Kuang Y, Dixit VM and Vincenz C:
Boo, a novel negative regulator of cell death, interacts with Apaf
1. EMBO J. 18:167–178. 1999. View Article : Google Scholar : PubMed/NCBI
|
33
|
Ichijo H: From receptors to
stress-activated MAP kinases. Oncogene. 18:6087–6093. 1999.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Carnero A: The PKB/AKT pathway in cancer.
Curr Pharm Des. 16:34–44. 2010. View Article : Google Scholar : PubMed/NCBI
|
35
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
36
|
Dhillon AS, Hangan S, Rath O and Kolch W:
MAP kinase signaling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
37
|
Ham SA, Yoo T, Hwang JS, Kang ES, Lee WJ,
Paek KS, Park C, Kim JH, Do JT, Lim DS and Seo HG: Ligand-activated
PPARδ modulates the migration and invasion of melanoma cells by
regulating Snail expression. Am. J Cancer Res. 4:674–682. 2014.
|
38
|
Rao KM: MAP kinase activation in
macrophages. J Leukoc Biol. 69:3–10. 2001.PubMed/NCBI
|
39
|
Lee JS, Seo HS, Kim SJ, Kim HJ, Kim J, Lee
SH, Park YS, Park BK, Kim BS, Kim SK and Jung JY: Studies on the
anticancer effect of apigenin in KB cell xenograft nude mouse
model. J Life Sci. 20:1519–1524. 2010. View Article : Google Scholar
|
40
|
Wang IK, Lin-Shiau SY and Lin JK:
Induction of apoptosis by apigenin and related flavonoids through
cytochrome c release and activation of caspase-9 and caspase-3 in
leukaemia HL-60 cells. Eur J Cancer. 35:1517–1525. 1999. View Article : Google Scholar : PubMed/NCBI
|
41
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
42
|
Erdogan S, Doganlar O, Doganlar ZB,
Serttas R, Turkekul K, Dibirdik I and Bilir A: The flavonoid
apigenin reduces prostate cancer CD44(+) stem cell survival and
migration through PI3K/Akt/NF-κB signaling. Life Sci. 162:77–86.
2016. View Article : Google Scholar : PubMed/NCBI
|
43
|
Toker A and Yoeli-Lerner M: Akt signaling
and cancer: Surviving but not moving on. Cancer Res. 66:3963–3966.
2006. View Article : Google Scholar : PubMed/NCBI
|
44
|
Choi EJ and Kim GH: Apigenin causes G(2)/M
arrest associated with the modulation of p21(Cip1) and Cdc2 and
activates p53-dependent apoptosis pathway in human breast cancer
SK-BR-3 cells. J Nutr Biochem. 20:285–290. 2009. View Article : Google Scholar : PubMed/NCBI
|
45
|
Shukla S and Gupta S: Molecular mechanisms
for apigenin-induced cell-cycle arrest and apoptosis of hormone
refractory human prostate carcinoma DU145 cells. Mol Carcinog.
39:114–126. 2004. View Article : Google Scholar : PubMed/NCBI
|
46
|
Shukla S and Gupta S: Apigenin-induced
cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and
loss of cyclin D1 associated retinoblastoma dephosphorylation in
human prostate cancer cells. Cell Cycle. 6:1102–1114. 2007.
View Article : Google Scholar : PubMed/NCBI
|
47
|
Lee WJ, Chen WK, Wang CJ, Lin WL and Tseng
TH: Apigenin inhibits HGF-promoted invasive growth and metastasis
involving blocking PI3K/Akt pathway and beta 4 integrin function in
MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol.
226:178–191. 2008. View Article : Google Scholar : PubMed/NCBI
|
48
|
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y and
Hu LL: ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med.
19:1997–2007. 2020.PubMed/NCBI
|
49
|
Yang S and Liu G: Targeting the
Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett.
13:1041–1047. 2017. View Article : Google Scholar : PubMed/NCBI
|
50
|
Patel AL and Shvartsman SY: Outstanding
questions in developmental ERK signaling. Development.
145:dev1438182018. View Article : Google Scholar : PubMed/NCBI
|
51
|
Zhao G, Han X, Cheng W, Ni J, Zhang Y, Lin
J and Song Z: Apigenin inhibits proliferation and invasion, and
induces apoptosis and cell cycle arrest in human melanoma cells.
Oncol Rep. 37:2277–2285. 2017. View Article : Google Scholar : PubMed/NCBI
|
52
|
Zhao M, Ma J, Zhu HY, Zhang XH, Du ZY, Xu
YJ and Yu XD: Apigenin inhibits proliferation and induces apoptosis
in human multiple myeloma cells through targeting the trinity of
CK2, Cdc37 and Hsp90. Mol Cancer. 10:1042011. View Article : Google Scholar : PubMed/NCBI
|
53
|
Jin XY and Ren CS: Effect and mechanism of
apigenin on VEGF expression in human breast cancer cells. Zhonghua
Zhong Liu Za Zhi. 29:495–499. 2007.(In Chinese). PubMed/NCBI
|
54
|
Lee SH, Ryu JK, Lee KY, Woo SM, Park JK,
Yoo JW, Kim YT and Yoon YB: Enhanced anti-tumor effect of
combination therapy with gemcitabine and apigenin in pancreatic
cancer. Cancer Lett. 259:39–49. 2008. View Article : Google Scholar : PubMed/NCBI
|
55
|
Pecorino L: Molecular biology of cancer:
Mechanisms, targets, and therapeutics. Oxford University Press; pp.
157–182. 2012
|
56
|
Yang Y, Zhu X, Chen Y, Wang X and Chen R:
p38 and JNK MAPK, but not ERK1/2 MAPK, play important role in
colchicine-induced cortical neurons apoptosis. Eur J Pharmacol.
576:26–33. 2007. View Article : Google Scholar : PubMed/NCBI
|
57
|
Ballif BA and Blenis J: Molecular
mechanisms mediating mammalian mitogen-activated protein kinase
(MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ.
12:397–408. 2001.PubMed/NCBI
|
58
|
Moos PJ and Fitzpatrick FA: Taxanes
propagate apoptosis via two cell populations with distinctive
cytological and molecular traits. Cell Growth Differ. 9:687–697.
1998.PubMed/NCBI
|